ALK and neoplasm: The ALK inhibitors, crizotinib and ceritinib, are in current clinical use for ALK-positive IMT.10,12,20,56 Therefore, the combinations of BV with crizotinib or ceritinib were evaluated based on the potential for rapid clinical translation as they have undergone early phase clinical trials in children and recommended phase 2 doses have been determined.12,13 In the diagnosis eIMS model, the combination of BV and crizotinib was highly efficacious, with all mice experiencing a CR and most animals confirmed as tumour-free at the end of the study (≥180 days post treatment).